Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
UNSPSC Code:
12352203
NACRES:
NA.41
eCl@ss:
32160702
Conjugate:
unconjugated
Clone:
polyclonal
Application:
ICC, IHC, WB
Citations:
1
biological source
rabbit
Quality Level
conjugate
unconjugated
antibody form
affinity isolated antibody
antibody product type
primary antibodies
clone
polyclonal
purified by
affinity chromatography
species reactivity
rat, human
technique(s)
immunocytochemistry: suitable, immunohistochemistry: suitable (paraffin), western blot: suitable
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
unmodified
Gene Information
human ... CAVIN1(284119)
General description
Polymerase I and transcript release factor (UniProt Q6NZI2; also known as Cavin-1, PTRF, RNA polymerase I and transcript release factor, TTF-I interacting peptide 12) is encoded by the PTRF (also known as CGL4, CAVIN, CAVIN1, FKSG13) gene (Gene ID 284119) in human. Cavin-1 is the founding member of the PTRF/Cavin family of cytoplasmic proteins whose expressions are essential for caveola formation. PTRF/Cavin-1, serum deprivation response (SDR)/Cavin-2, SDR-related gene product that binds to C kinase (SRBC)/Cavin-3, and muscle-restricted coiled-coil protein (MURC)/Cavin-4, form an oligomeric assembly termed Cavin complex in the cytosol and associate with caveolin at plasma membrane caveolae. Research shows an essential role for PTRF/Cavin-1 but not the other family members in caveola formation and recruitment of the cavin complex to the plasma membrane. In prostate cancer PC3 cells and during development of zebrafish notochord, lack of PTRF-Cavin expression correlates with lack of caveolae, where caveolin displays increased lateral mobility on the plasma membrane and accelerated lysosomal degradation. Expression of Cavin-1 restores caveolae formation in PC3 cells. Likewise the absence of cavin-1 is also observed in advanced prostate carcinoma. PTRF gene mutations are known to cause congenital generalized lipodystrophy 4 (CGL4).
~52 kDa observed.
Immunogen
Linear peptide corresponding to the N-terminus of human PTRF/Cavin-1.
Application
Anti-PTRF/Cavin-1 Antibody is an antibody against PTRF/Cavin-1 for use in Western Blotting, Immunohistochemistry (Paraffin), Immunocytochemistry.
Western Blotting Analysis: A representative lot detected PTRF/Cavin-1 expression in HeLa, but not in prostate cancer cell lines, LNCaP, 22Rv1 and PC-3 (Moon, H., et al. (2014). Oncogene 33(27):3561-3570).
Western Blotting Analysis: A representative lot detected exogenously expressed human PTRF/Cavin-1 in transfected 22Rv1 and LNCaP cells (Moon, H., et al. (2014). Oncogene 33(27):3561-3570).
Immunohistochemistry Analysis: A representative lot detected reduced PTRF/Cavin-1 immunoreactivity in paraffin-embedded malignant prostate stroma tissue samples when compared with normal prostate stroma and benign prostatic hyperplasia (BPH) specimens. A lack of PTRF/cavin-1 immunoreactivity in prostate epithelia was seen among both normal and malignant samples (Moon, H., et al. (2014). Oncogene 33(27):3561-3570).
Immunocytochemistry Analysis: A representative lot detected surface caveola localization of exogenously expressed human PTRF/Cavin-1 among transfected LNCaP cells (Moon, H., et al. (2014). Oncogene 33(27):3561-3570).
Western Blotting Analysis: A representative lot detected exogenously expressed human PTRF/Cavin-1 in transfected 22Rv1 and LNCaP cells (Moon, H., et al. (2014). Oncogene 33(27):3561-3570).
Immunohistochemistry Analysis: A representative lot detected reduced PTRF/Cavin-1 immunoreactivity in paraffin-embedded malignant prostate stroma tissue samples when compared with normal prostate stroma and benign prostatic hyperplasia (BPH) specimens. A lack of PTRF/cavin-1 immunoreactivity in prostate epithelia was seen among both normal and malignant samples (Moon, H., et al. (2014). Oncogene 33(27):3561-3570).
Immunocytochemistry Analysis: A representative lot detected surface caveola localization of exogenously expressed human PTRF/Cavin-1 among transfected LNCaP cells (Moon, H., et al. (2014). Oncogene 33(27):3561-3570).
Biochem/physiol Actions
Expected to react with spliced isoforms 1 and 2, but not isoform 3.
Analysis Note
Evaluated by Western Blotting in rat skeletal muscle myoblast L6 cell lysate.
Western Blotting Analysis: A 1:1,000 dilution of this antibody detected PTRF/Cavin-1 in 10 µg of rat skeletal muscle myoblast L6 cell lysate.
Western Blotting Analysis: A 1:1,000 dilution of this antibody detected PTRF/Cavin-1 in 10 µg of rat skeletal muscle myoblast L6 cell lysate.
Other Notes
Concentration: Please refer to lot specific datasheet.
Still not finding the right product?
Explore all of our products under Anti-PTRF/Cavin-1 Antibody
— or —
Try our Product Selector Tool to narrow your options
Storage Class
12 - Non Combustible Liquids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Bayader Annabi et al.
International journal of stem cells, 10(1), 103-113 (2016-12-28)
Tumour necrosis factor (TNF)-α activation of mesenchymal stromal cells (MSC) enhances their tumour-suppressive properties and tumour-homing ability. The molecular actors involved are unknown. We found that TNF induced MSC migration and tubulogenesis which correlated with a dose-dependent increase in Cavin-1
Global Trade Item Number
| SKU | GTIN |
|---|---|
| ABE1953 | 04055977299977 |